公开(公告)号：WO02055100A9

公开(公告)日：2006-05-11

申请号：PCT/US0151339

申请日：2001-10-22

Applicant: BERZOFSKY JAY A ,  TERABE MASAKI ,  DONALDSON DEBRA D ,  MATSUI SO ,  NOBEN-TRAUTH NANCY ,  PAUL WILLIAM E ,  INST GENETICS LLC ,  US GOV HEALTH & HUMAN SERV

Inventor： BERZOFSKY JAY A ,  TERABE MASAKI ,  DONALDSON DEBRA D ,  MATSUI SO ,  NOBEN-TRAUTH NANCY ,  PAUL WILLIAM E

IPC: A61K47/34 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P31/12 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20 ,  A61P35/00 ,  A61P35/02 ,  A61P37/04 ,  C07K14/54 ,  C07K16/24 ,  C07K16/28

CPC classification number: C07K16/244 ,  A61K38/1793 ,  A61K38/208 ,  A61K39/39 ,  A61K2039/505 ,  A61K2039/55516 ,  A61K2039/55538 ,  C07K16/2812 ,  C07K2319/30 ,  A61K2300/00

Abstract: Provided is a method and composition for enhancing an immune response in a subject by administering to the subject an inhibitor of IL-13 or an inhibitor of an NK-T cell to the subject. The method can be used to prevent growth of a tumor in the subject, e.g., to inhibit tumor recurrence or metastasis. The method can also be used to enhance a response to a vaccine in a subject.

Abstract translation: 本发明提供了一种通过向受试者施用IL-13抑制剂或NK-T细胞抑制剂来增强受试者的免疫应答的方法和组合物。 该方法可用于预防受试者中肿瘤的生长，例如抑制肿瘤复发或转移。 该方法还可用于增强对受试者中疫苗的反应。

公开(公告)号：WO0186002A3

公开(公告)日：2003-09-04

申请号：PCT/US0115118

申请日：2001-05-09

Applicant: INST GENETICS LLC ,  UNIV ROCKEFELLER

Inventor： TREPICCHIO WILLIAM L ,  OESTREICHER JUDITH L ,  DORNER ANDREW J ,  KRUEGER JAMES G

IPC: C12N15/09 ,  A61K31/7088 ,  A61K38/00 ,  A61K45/00 ,  A61K48/00 ,  A61P17/06 ,  A61P43/00 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/569 ,  G01N33/574 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  C12Q1/6876 ,  C12Q2600/158 ,  G01N33/56972

Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating psoriasis. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of psoriasis.

Abstract translation: 本发明涉及用于检测，表征，预防和治疗牛皮癣的组合物，试剂盒和方法。 提供了多种标志物，其中一种或多种标志物的表达水平的变化与牛皮癣的存在相关。

公开(公告)号：WO02066059A3

公开(公告)日：2003-08-07

申请号：PCT/US0204772

申请日：2002-02-15

Applicant: INST GENETICS LLC

Inventor： O'HARA RICHARD M JR ,  NAGELIN ANN MARIE

IPC: A61P37/06 ,  C07K16/28 ,  A61K39/395 ,  A61K38/00

CPC classification number: C07K16/2818 ,  A61K2039/505 ,  C07K2317/622

Abstract: The instant invention provides compositions and methods for downmodulation of immune responses, e.g., autoimmune responses. For example, methods of downmodulating an immune response using agents that specifically block CD28-mediated signaling are provided. The subject methods are useful for both prophylactic and therapeutic downmodulation of immune responses.

Abstract translation: 本发明提供了用于免疫应答下调的组合物和方法，例如自身免疫应答。 例如，提供了使用特异性阻断CD28介导的信号传导的试剂下调免疫应答的方法。 主题方法对于免疫应答的预防性和治疗性下调都是有用的。

公开(公告)号：WO0200730A9

公开(公告)日：2003-07-10

申请号：PCT/US0120964

申请日：2001-06-28

Applicant: INST GENETICS LLC ,  DANA FARBER CANCER INST INC

Inventor： FREEMAN GORDON ,  CHERNOVA IRENE ,  CHERNOVA TATYANA ,  MALENKOVICH NELLY ,  WOOD CLIVE

IPC: A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  A61P3/10 ,  A61P11/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/08 ,  C07K14/705 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/566 ,  G01N33/573 ,  G01N33/68 ,  A61K38/00

CPC classification number: G01N33/6854 ,  G01N33/5014 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/573 ,  G01N2800/52

Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

Abstract translation: 本发明提供分离的核酸分子，命名为PD-L2核酸分子，其编码作为PD-1配体的新型B7相关分子。 本发明还提供了反义核酸分子，含有PD-L2核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及已导入或破坏了PD-L2基因的非人类转基因动物。 本发明进一步提供分离的PD-L2多肽，融合蛋白，抗原肽和抗-PD-L2抗体。 本发明还提供了促进或抑制PD-L2与PD-1之间相互作用的方法。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：WO02066059A8

公开(公告)日：2003-03-13

申请号：PCT/US0204772

申请日：2002-02-15

Applicant: INST GENETICS LLC

Inventor： O'HARA RICHARD M JR ,  NAGELIN ANN MARIE

IPC: A61P37/06 ,  C07K16/28 ,  A61K39/395 ,  A61K38/00

CPC classification number: C07K16/2818 ,  A61K2039/505 ,  C07K2317/622

Abstract: The instant invention provides compositions and methods for downmodulation of immune responses, e.g., autoimmune responses. For example, methods of downmodulating an immune response using agents that specifically block CD28-mediated signaling are provided. The subject methods are useful for both prophylactic and therapeutic downmodulation of immune responses.

Abstract translation: 本发明提供了用于免疫应答下调的组合物和方法，例如自身免疫应答。 例如，提供使用特异性阻断CD28介导的信号传导的试剂下调免疫应答的方法。 本发明方法对预防和治疗免疫应答的下调是有用的。

公开(公告)号：WO0246770A3

公开(公告)日：2004-02-26

申请号：PCT/US0150744

申请日：2001-10-22

Applicant: INST GENETICS LLC

Inventor： QIU YONGCHANG ,  WANG JACK H ,  HEWICK RODNEY M

IPC: G01N27/62 ,  G01N27/447 ,  G01N27/64 ,  G01N33/483 ,  G01N33/68 ,  C07C279/14 ,  C07D207/456 ,  G01N33/58

CPC classification number: G01N33/6848 ,  G01N33/6851 ,  G01N2458/15 ,  Y10T436/13 ,  Y10T436/24 ,  Y10T436/25125

Abstract: Arginine-containing cysteine-modifying compounds useful for MALDI-MS analysis of proteins are provided. These compounds termed isotope-coded ionization enhancement reagents (ICIER) can provide ionization enhancement in MALDI-MS, relative quantitation, and additional database searching constraints at the same time without any extra sample manipulation. More specifically, ICIER increase the ionization efficiency of cysteine-containing peptides by attachment of a guanidino functional group. ICIER also increase the overall hydrophilicity of these peptides due the hydrophilic nature of ICIER and thus increase the percentage of recovery of these peptides during sample handling and processing such as in-gel digestion or liquid chromatography. Finally, a combination of both light and heavy ICIER provides an accurate way to obtain relative quantitation of proteins by MALDI-MIS and additional database searching constraints (number of cysteine residues in every single peptide peak) to increase the confidence of protein identification by peptide mass mapping.

Abstract translation: 提供了可用于蛋白质MALDI-MS分析的含精氨酸的半胱氨酸修饰化合物。 这些称为同位素编码电离增强试剂（ICIER）的化合物可以在MALDI-MS中提供电离增强，相对定量和额外的数据库搜索约束，同时没有任何额外的样品操作。 更具体地，ICIER通过连接胍基官能团来增加含半胱氨酸的肽的电离效率。 由于ICIER的亲水性，ICIER还增加了这些肽的整体亲水性，因此增加了样品处理和加工（如凝胶内消化或液相色谱法）过程中这些肽的回收百分比。 最后，轻和重ICIER的组合提供了通过MALDI-MIS和附加的数据库搜索约束（每个肽峰中的半胱氨酸残基的数目）获得蛋白质的相对定量的精确方式，以增加肽质量的蛋白质鉴定的置信度 映射。

公开(公告)号：WO0238767A3

公开(公告)日：2003-09-04

申请号：PCT/US0149696

申请日：2001-11-07

Applicant: INST GENETICS LLC ,  GULUKOTA KAMALAKAR ,  KAUR HARLEEN ,  BATES BRIAN G ,  PAULSEN JANET E

Inventor： GULUKOTA KAMALAKAR ,  KAUR HARLEEN ,  BATES BRIAN G ,  PAULSEN JANET E

IPC: A61K38/00 ,  A61K48/00 ,  C07K14/72 ,  C12N15/12 ,  A01K67/027 ,  C07K14/705 ,  C07K16/28 ,  C12N5/10 ,  C12Q1/68 ,  G01N33/577 ,  G01N33/68

CPC classification number: C07K14/723 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00

Abstract: Novel C5RL polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length C5RL proteins, the invention further provides isolated C5RL fusion proteins, antigenic peptides and anti-C5RL antibodies. The invention also provides C5RL nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a C5RL gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Abstract translation: 公开了新的C5RL多肽，蛋白质和核酸分子。 除了分离的全长C5RL蛋白之外，本发明还提供了分离的C5RL融合蛋白，抗原肽和抗C5RL抗体。 本发明还提供了C5RL核酸分子，含有本发明的核酸分子的重组表达载体，已经引入了表达载体的宿主细胞和已引入或破坏了C5RL基因的非人转基因动物。 还提供利用本发明组合物的诊断，筛选和治疗方法。

公开(公告)号：WO02066045A3

公开(公告)日：2003-08-21

申请号：PCT/US0204469

申请日：2002-02-15

Applicant: INST GENETICS LLC ,  JOHN P ROBERTS RES INST INC ,  BRIGHAM & WOMENS HOSPITAL

Inventor： COLLINS MARY ,  MADRENAS JOACHIM ,  CARRENO BEATRIZ ,  KUCHROO VIJAY

IPC: A61K38/08 ,  A61K38/17 ,  A61K38/46 ,  A61P37/06 ,  G01N33/50 ,  A61K31/00

CPC classification number: G01N33/505 ,  A61K38/177 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/502 ,  G01N33/5041 ,  G01N2333/70521 ,  G01N2333/916 ,  G01N2500/10

Abstract: The present invention provides methods for modulating an immune response comprising contacting a cell with an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention further provides methods for treating a subject having a disorder that would benefit from down regulation of an immune response comprising administering an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention also provides methods for identifying compounds capable of modulating the interaction of CTLA4 and PP2AA.

Abstract translation: 本发明提供了调节免疫应答的方法，包括使细胞与通过调节CTLA4的赖氨酸富集基序调节CTLA4和PP2AA之间的相互作用的试剂接触。 本发明还提供了治疗受益于免疫应答下调的疾病的受试者的方法，包括通过调节CTLA4和赖氨酸赖氨酸基序调节CTLA4和PP2AA之间的相互作用的药剂。 本发明还提供了鉴定能够调节CTLA4和PP2AA相互作用的化合物的方法。

公开(公告)号：WO0185792A3

公开(公告)日：2003-08-21

申请号：PCT/US0115395

申请日：2001-05-11

Applicant: INST GENETICS LLC ,  DONALDSON DEBRA D ,  UNGER MICHELLE J ,  YOUNG DEBORAH A ,  WHITTERS MATTHEW J ,  LOWE LESLIE ,  COLLINS MARY

Inventor： DONALDSON DEBRA D ,  UNGER MICHELLE J ,  YOUNG DEBORAH A ,  WHITTERS MATTHEW J ,  LOWE LESLIE ,  COLLINS MARY

IPC: C12N15/09 ,  A61K38/00 ,  A61P37/04 ,  A61P37/06 ,  A61P37/08 ,  C07K14/715 ,  C07K16/28 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/12 ,  C12P21/02 ,  A61K38/17 ,  C12N15/66

CPC classification number: C07K14/715 ,  A61K38/00 ,  C07K2319/30

Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.

Abstract translation: 公开了编码MU-1造血细胞因子受体超家族链及其片段的多核苷酸。 还公开了MU-1蛋白质及其生产方法。

公开(公告)号：WO02068476A3

公开(公告)日：2003-08-07

申请号：PCT/US0205684

申请日：2002-02-25

Applicant: INST GENETICS LLC ,  JACOBS KENNETH ,  PITTMAN DEBRA ,  FOUSER LYNETTE ,  SPAULDING VIKKI ,  XUAN DEJUN

Inventor： JACOBS KENNETH ,  PITTMAN DEBRA ,  FOUSER LYNETTE ,  SPAULDING VIKKI ,  XUAN DEJUN

IPC: C12P21/08 ,  A61K38/20 ,  A61K39/395 ,  A61P1/04 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P17/02 ,  A61P17/06 ,  A61P19/04 ,  A61P21/04 ,  A61P25/00 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/08 ,  A61P39/06 ,  C07K14/54 ,  C07K16/24 ,  A61K38/00

CPC classification number: C07K16/244 ,  A61K38/20 ,  A61K2039/505 ,  C07K14/54 ,  C07K14/5428 ,  C12N2710/10043 ,  C12N2799/022 ,  A61K2300/00

Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.

Abstract translation: 公开了IL-22的抑制剂以及药物组合物及其使用方法。 抑制剂包括IL-22抗体，可用于治疗炎性疾病。